Tübingen and Frankfurt (Germany), October 20, 2022 – Today, Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced its participation in upcoming industry and investor conferences. Atriva will present the latest clinical data for their lead product zapnometinib (ATR-002) and discuss its potential as a first-in-class therapy with established proof-of-concept for use against a wide range of viral diseases with high pandemic risk. Further information about the company, its drug development capabilities and programs can be found online at www.atriva-therapeutics.com. Meetings can be requested either via the conferences’ partnering platform or via email to lichtenberger@atriva-therapeutics.com.
| BIO-Europe® October 24th – 26th, 2022, Leipzig Messe, Germany Rainer Lichtenberger, Ph.D., CEO of Atriva Therapeutics, and Stephan Stenglein, MD, CMO will be personally available for presenting, networking, partnering and one-on-one discussions. https://informaconnect.com/bioeurope/ |
| BioFuture™ November 7th – 9th, 2022, Lotte New York Palace, US Dr. Rainer Lichtenberger and non-executive director Michael Grissinger will present Atriva’s technology and development programs and will be available for partnering meetings. https://biofuture.com/venue/ |
| ChinaBio® November 10th – 11th, 2022, virtual Atriva Therapeutics management team will be available for partnering discussions via the partneringONE platform. https://informaconnect.com/chinabio-partnering/ |
| LSX Inv€$tival Showcase™ November 14th, 2022, Old Billingsgate London, UK Atriva Therapeutics management will be available for networking and investor and partnering meetings. https://www.lsxleaders.com/investival-showcase |
| BioCentury-BayHelix East-West Summit 2022 November 14th – 16th, 2022, Grand Bay Hotel San Francisco, Redwood City, US Atriva Therapeutics management team will be available online for investor and partnering discussions. https://conferences.biocentury.com/east-west-summit |
| BARDA Industry Day (BID) November 15th – 16th, 2022, virtual; Atriva Therapeutics Management will be available to discuss their technology and projects. https://www.medicalcountermeasures.gov/barda/barda-industry-day-2022/ |
| Jefferies 2022 London Healthcare Conference November 15th – 17th, 2022, London, UK Atriva Therapeutics management will be available for networking, 1:1 partnering and investor discussions. https://www.jefferies.com/OurFirm/ConferenceList/Investment-Conferences/159 |
| Biotechgate Digital Partnering November 28th – December 2nd, 2022, virtual; Atriva Therapeutics management will be available for networking, 1:1 partnering and investor discussions https://www.digitalpartnering.com/ |
| JPM 2023, 41st Annual Healthcare Meeting January 9th – 12th, The Westin St. Francis San Francisco, US Atriva Therapeutics management team will be available for investor and partnering meetings and networking. https://jpmhealthcareconference.com/ |
| Biotech Showcase January 9th – 11th, The Westin St. Francis San Francisco, US January 18th – 19th, virtual Atriva Therapeutics management will present the technology and will be available for 1:1 partnering and investor meetings. https://informaconnect.com/biotech-showcase/ |
About Atriva Therapeutics
Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical need induced by RNA viruses, e.g., influenza and COVID-19. The clinical-stage biopharmaceutical company is pioneering the development of host-targeting antiviral therapies, making development of viral resistance unlikely, and thereby significantly contributing to pandemic preparedness. The Atriva lead product zapnometinib (ATR-002) is a first-in-class, host-targeting agent that aims to inhibit viral replication and to favorably modulate the body’s immune response to RNA viruses. Atriva Therapeutics was founded in 2015 by a team of leading scientists in viral research and seasoned industry experts.
Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de
For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter.
Contact:
Atriva Therapeutics GmbH
Christian Pangratz
+49 69 999916210
info@atriva-therapeutics.com
References:
[1] Atriva Therapeutics GmbH. 2022. A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19 (RESPIRE).
[2] https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis.
[3] Pleschka S et al. Nat Cell Biol 2001 Feb 3:301-5.
[4] Pleschka S. 2008. Biol Chem. 389, 1273–1282.
[5] Haasbach E et al. Antiviral Res 2017 Jun 142:178-4.
[6] Laure M et al. Antiviral Res 2020 Jun 178:104806.
[7] Schreiber A et al. 2022. Cell Mol Life Sci. 79(1):65.
[8] Planz O Antiviral Res 2013 Jun 98(3):457-68.
[9] Pinto R et al. Antiviral Res 2011 Oct 92(1):45-56.
[10] Ragab D et al. 2020. Front Immunol. 11, 1446 (2020).